Clear Search sequence regions


  • cancers (1)
  • carfilzomib (10)
  • cell death (3)
  • eIF2α (1)
  • heat (1)
  • humans (1)
  • hyperthermia (10)
  • multiple myeloma (11)
  • NRF2 (1)
  • oligopeptides (2)
  • PIM2 (1)
  • plasmacytoma (1)
  • research (1)
  • subunit (2)
  • Sizes of these terms reflect their relevance to your search.

    Hyperthermia is a unique treatment option for cancers. Multiple myeloma (MM) remains incurable and innovative therapeutic options are needed. We investigated the efficacy of hyperthermia and carfilzomib in combination against MM cells. Although MM cell lines exhibited different susceptibilities to pulsatile carfilzomib treatment, mild hyperthermia at 43℃ induced MM cell death in all cell lines in a time-dependent manner. Hyperthermia and carfilzomib cooperatively induced MM cell death even under suboptimal conditions. The pro-survival mediators PIM2 and NRF2 accumulated in MM cells due to inhibition of their proteasomal degradation by carfilzomib; however, hyperthermia acutely suppressed translation in parallel with phosphorylation of eIF2α to reduce these proteins in MM cells. Recovery of β5 subunit enzymatic activity from its immediate inhibition by carfilzomib was observed at 24 h in carfilzomib-insusceptible KMS-11, OPM-2, and RPMI8226 cells, but not in carfilzomib-sensitive MM.1S cells. However, heat treatment suppressed the recovery of β5 subunit activity in these carfilzomib-insusceptible cells. Therefore, hyperthermia re-sensitized MM cells to carfilzomib. Our results support the treatment of MM with hyperthermia in combination with carfilzomib. Further research is warranted on hyperthermia for drug-resistant extramedullary plasmacytoma. © 2024. Japanese Society of Hematology.

    Citation

    Tomoko Maruhashi, Hirokazu Miki, Kimiko Sogabe, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Mamiko Takahashi, Takeshi Harada, Shiro Fujii, Shingen Nakamura, Kiyoe Kurahashi, Itsuro Endo, Masahiro Abe. Acute suppression of translation by hyperthermia enhances anti-myeloma activity of carfilzomib. International journal of hematology. 2024 Mar;119(3):291-302

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38252236

    View Full Text